A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Clinical trial NCT06319456 · RECRUITING
Trial details
- NCT number
- NCT06319456
- Sponsor
- Ascentage Pharma Group Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-07
- Primary completion
- 2027-08-01
- Enrollment
- 344
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.